Quantum Biopharma (QNTM) Competitors

Quantum Biopharma logo
$1.42 -0.10 (-6.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.43 +0.01 (+0.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QNTM vs. ZYBT, HRTX, FBIO, CGTX, and CING

Should you buy Quantum Biopharma stock or one of its competitors? Quantum Biopharma's main competitors and comparable companies include Zhengye Biotechnology (ZYBT), Heron Therapeutics (HRTX), Fortress Biotech (FBIO), Cognition Therapeutics (CGTX), and Cingulate (CING). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Quantum Biopharma compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Zhengye Biotechnology has a beta of -2.33, suggesting that its stock price is 333% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Quantum Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$16.64M4.27-$9.98MN/AN/A
Quantum BiopharmaN/AN/A-$26.17M-$4.30N/A

In the previous week, Quantum Biopharma had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Quantum Biopharma and 4 mentions for Zhengye Biotechnology. Quantum Biopharma's average media sentiment score of 0.42 beat Zhengye Biotechnology's score of 0.02 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zhengye Biotechnology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quantum Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zhengye Biotechnology's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Quantum Biopharma N/A -412.03%-139.32%

Quantum Biopharma has a consensus price target of $8.00, suggesting a potential upside of 426.32%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Quantum Biopharma is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Quantum Biopharma beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Quantum Biopharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -14.55%. Heron Therapeutics' return on equity of -277.36% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-14.55% -277.36% -8.76%
Quantum Biopharma N/A -412.03%-139.32%

Heron Therapeutics currently has a consensus price target of $2.00, indicating a potential upside of 632.60%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 426.32%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Quantum Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

In the previous week, Heron Therapeutics had 5 more articles in the media than Quantum Biopharma. MarketBeat recorded 10 mentions for Heron Therapeutics and 5 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.42 beat Heron Therapeutics' score of -0.53 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Quantum Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Heron Therapeutics has higher revenue and earnings than Quantum Biopharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.34-$20.19M-$0.12N/A
Quantum BiopharmaN/AN/A-$26.17M-$4.30N/A

Summary

Heron Therapeutics beats Quantum Biopharma on 9 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Fortress Biotech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Fortress Biotech has a net margin of 143.04% compared to Quantum Biopharma's net margin of 0.00%. Fortress Biotech's return on equity of 61.84% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortress Biotech143.04% 61.84% 35.15%
Quantum Biopharma N/A -412.03%-139.32%

Fortress Biotech has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortress Biotech$63.26M1.01$6.82M$2.300.82
Quantum BiopharmaN/AN/A-$26.17M-$4.30N/A

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 799.47%. Quantum Biopharma has a consensus price target of $8.00, suggesting a potential upside of 426.32%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Fortress Biotech is more favorable than Quantum Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Fortress Biotech had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Fortress Biotech and 5 mentions for Quantum Biopharma. Fortress Biotech's average media sentiment score of 0.65 beat Quantum Biopharma's score of 0.42 indicating that Fortress Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortress Biotech
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quantum Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Fortress Biotech beats Quantum Biopharma on 14 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 455.56%. Quantum Biopharma has a consensus price target of $8.00, suggesting a potential upside of 426.32%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cognition Therapeutics is more favorable than Quantum Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Quantum Biopharma had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Quantum Biopharma and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.89 beat Quantum Biopharma's score of 0.42 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quantum Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cognition Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$23.49M-$0.15N/A
Quantum BiopharmaN/AN/A-$26.17M-$4.30N/A

Cognition Therapeutics' return on equity of -50.57% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -50.57% -40.42%
Quantum Biopharma N/A -412.03%-139.32%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cognition Therapeutics beats Quantum Biopharma on 11 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Cingulate?

Cingulate (NASDAQ:CING) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Cingulate has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Cingulate presently has a consensus price target of $27.00, indicating a potential upside of 428.38%. Quantum Biopharma has a consensus price target of $8.00, indicating a potential upside of 426.32%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Quantum Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Quantum Biopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cingulate's return on equity of -177.94% beat Quantum Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -177.94% -108.95%
Quantum Biopharma N/A -412.03%-139.32%

Cingulate is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$22.45M-$2.77N/A
Quantum BiopharmaN/AN/A-$26.17M-$4.30N/A

In the previous week, Quantum Biopharma had 1 more articles in the media than Cingulate. MarketBeat recorded 5 mentions for Quantum Biopharma and 4 mentions for Cingulate. Quantum Biopharma's average media sentiment score of 0.42 beat Cingulate's score of -0.31 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cingulate
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quantum Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cingulate beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNTM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNTM vs. The Competition

MetricQuantum BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$12.29M$13.12B$7.47B$11.44B
Dividend YieldN/A2.59%2.47%4.64%
P/E RatioN/A27.5632.7729.51
Price / SalesN/A7.498.005.30
Price / CashN/A15.5920.8521.62
Price / Book1.175.294.383.65
Net Income-$26.17M$2.87B$3.51B$394.00M
7 Day Performance-20.22%-5.84%-6.16%-6.39%
1 Month Performance-41.08%-6.83%-7.05%-8.77%
1 Year Performance-77.50%-7.91%-2.52%-8.47%

Quantum Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QNTM
Quantum Biopharma
1.8992 of 5 stars
$1.42
-6.6%
$8.00
+463.4%
-77.6%$12.29MN/AN/A17
ZYBT
Zhengye Biotechnology
0.6348 of 5 stars
$1.54
+3.4%
N/A-29.6%$70.61M$16.64MN/A269
HRTX
Heron Therapeutics
1.7278 of 5 stars
$0.37
+0.9%
$2.00
+434.6%
-75.6%$70.36M$154.90MN/A128
FBIO
Fortress Biotech
2.733 of 5 stars
$1.91
-4.0%
$17.00
+790.1%
-29.2%$66.37M$63.26M0.7278
CGTX
Cognition Therapeutics
1.8411 of 5 stars
$0.67
-3.0%
$3.33
+397.4%
-60.5%$65.68MN/AN/A14

Related Companies and Tools


This page (NASDAQ:QNTM) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners